Form 4: ResMed Director Peter C. Farrell Sells 2,000 Shares Under 10b5-1 Plan
SEC Form 4 Filing
Peter C. Farrell, a director at ResMed Inc., sold 2,000 shares of common stock on January 2, 2025, under a pre-arranged Rule 10b5-1 trading plan.
Summary
- On January 2, 2025, Peter C. Farrell, a director of ResMed Inc. (RMD), sold 2,000 shares of ResMed common stock.
- The sale was executed at a price of $230.99 per share.
- The transaction was conducted under a Rule 10b5-1 plan adopted on May 28, 2024.
- Following the transaction, Farrell directly owns 79,218 shares of ResMed common stock.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing related to a share sale by a company director. It doesn't inherently convey positive or negative sentiment, as it's a routine transaction under a pre-arranged plan.
Industry Context
Sales by company insiders are a common occurrence and are often related to personal financial planning. The use of a 10b5-1 plan allows insiders to sell shares at predetermined times and prices, avoiding accusations of trading on inside information.
Stakeholder Impact
- The sale of shares by a director could have a minor negative impact on shareholder sentiment, but the existence of a 10b5-1 plan mitigates this concern.
Key Dates
| Date | Description |
|---|---|
| May 28, 2024 | Date of adoption of the Rule 10b5-1 plan |
| January 2, 2025 | Date of the transaction (sale of shares) |
| January 3, 2025 | Date of signature on the Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.